NIAID Announces Phase 1 Clinical Trial Evaluating Investigational COVID-19 Vaccine

HHS: Secretary Azar Statement on Launch of Phase 1 COVID-19 Vaccine Trial
“On Monday, the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health announced that a Phase 1 clinical trial evaluating an investigational vaccine designed to protect against COVID-19 has begun at Kaiser Permanente Washington Health Research Institute in Seattle, funded by NIH. … The study is evaluating different doses of the experimental vaccine for safety and its ability to induce an immune response in participants…” (3/16).

NIH: NIH clinical trial of investigational vaccine for COVID-19 begins
“…The open-label trial will enroll 45 healthy adult volunteers ages 18 to 55 years over approximately 6 weeks. The first participant received the investigational vaccine [on Monday]. The study is evaluating different doses of the experimental vaccine for safety and its ability to induce an immune response in participants. This is the first of multiple steps in the clinical trial process for evaluating the potential benefit of the vaccine…” (3/16).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

The Henry J. Kaiser Family Foundation Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KaiserFamilyFoundation | twitter.com/kff

Filling the need for trusted information on national health issues, the Kaiser Family Foundation is a nonprofit organization based in San Francisco, California.